Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: Relationship with oxidative stress improvement

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 25, Issue 2, 2015, Pages 153-159

  Zinellu, A ^a   Sotgia, S ^a   Mangoni, A A ^b   Sanna, M ^a   Satta, A E ^a   Carru, C ^a,c  

^a UNIVERSITY OF SASSARI   (Italy)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY HOSPITAL OF SASSARI   (Italy)

Author keywords

Chronic kidney disease; CKD; IDO; Inflammation; Kyn; Kynurenine; OS; Oxidative stress; Trp; Tryptophan

Indexed keywords

ALLANTOIN; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; SIMVASTATIN; TAURINE; TRYPTOPHAN; URIC ACID;

ADULT; ARTICLE; CAPILLARY ELECTROPHORESIS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG DOSE COMPARISON; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84964292923     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.11.004     Document Type: Article

References (30)

1. Ruddick J.P., Evans A.K., Nutt D.J., Lightman S.L., Rook G.A., Lowry C.A. Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med 2006, 8:1-27.
2. Gál E.M., Sherman A.D. L-kynurenine: Its synthesis and possible regulatory function in brain. Neurochem Res 1980, 5:223-229.
3. Salter M., Pogson C.I. The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem J 1985, 229:499-504.
4. Takikawa O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys Res Commun 2005, 338:12-19.
5. Guillemin G.J., Smythe G., Takikawa O., Brew B.J. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005, 49:15-23.
6. Maes M., der Planken V., Van Gastel A., Desnyder R. Blood coagulation and platelet aggression in major depression. J Affect Disord 1996, 40:35-40.
7. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001, 158:1252-1257.
8. Capuron L., Schroecksnadel S., Feart C., Aubert A., Higueret D., Barberger-Gateau P., et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 2011, 70:175-182.
9. Nakanishi I., Moutabarrik A., Okada N., Kitamura E., Hayashi A., Syouji T., et al. Interleukin-8 in chronic renal failure and dialysis patients. Nephrol Dial Transplant 1994, 9:1435-1442.
10. Cachofeiro V., Goicochea M., de Vinuesa S.G., Oubiña P., Lahera V., Luño J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008, 111:S4-S9.
11. Kimmel P.L., Phillips T.M., Simmens S.J., Peterson R.A., Weihs K.L., Alleyne S., et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998, 54:236-244.
12. Manjunath G., Tighiouart H., Coresh J., Macleod B., Salem D.N., Griffith J.L., et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003, 63:1121-1129.
13. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003, 108:2154-2169.
14. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006, 290:F262-F272.
15. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. ASCOT investigators: prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
16. Zoja C., Corna D., Gagliardini E., Conti S., Arnaboldi L., Benigni A., et al. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol 2010, 299:F1203-F1211.
17. Dembowski E., Davidson M.H. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2009, 16:183-188.
18. Goicoechea M., de Vinuesa S.G., Lahera V., Cachofeiro V., Gómez-Campderá F., Vega A,Abad S., et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006, 17:S231-S235.
19. Zinellu A., Sotgia S., Deiana L., Talanas G., Terrosu P., Carru C. Simultaneous analysis of kynurenine and tryptophan in human plasma by capillary electrophoresis with UV detection. J Sep Sci 2012, 35:1146-1151.
20. Zinellu A., Sotgia S., Deiana L., Carru C. Field-amplified online sample stacking capillary electrophoresis UV detection for plasma malondialdehyde measurement. Electrophoresis 2011, 32:1893-1897.
21. Zinellu A., Sotgia S., Deiana L., Carru C. Field-amplified sample injection combined with pressure-assisted capillary electrophoresis UV detection for the simultaneous analysis of allantoin, uric acid, and malondialdehyde in human plasma. Anal Bioanal Chem 2011, 399:2855-2861.
22. Zinellu A., Sotgia S., Scanu B., Chessa R., Gaspa L., Franconi F., et al. Taurine determination by capillary electrophoresis with laser-induced fluorescence detection: from clinical field to quality food applications. Amino Acids 2009, 36:35-41.
23. Zinellu A., Loriga G., Scanu B., Pisanu E., Sanna M., Deiana L., et al. Increased low-density lipoprotein S-homocysteinylation in chronic kidney disease. Am J Nephrol 2010, 32:242-248.
24. Zinellu A., Sotgia S., Loriga G., Deiana L., Satta A.E., Carru C. Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy. Amino Acids 2012, 43:1499-1507.
25. Kostapanos M.S., Milionis H.J., Elisaf M.S. An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 2008, 13:157-174.
26. Conard S., Bays H., Leiter L.A., Bird S., Lin J., Hanson M.E., et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 2010, 12:210-218.
27. Stein E.A., Ballantyne C.M., Windler E., Sirnes P.A., Sussekov A., Yigit Z., et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008, 101:490-496.
28. Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., Reibnegger G., Wachter H. Characteristics of interferon-induced tryptophan metabolism in human cells invitro. Biochem Biophys Acta 1989, 1012:140-147.
29. Zhao J. Plasma kynurenic acid/tryptophan ratio: a sensitive and reliable biomarker for the assessment of renal function. Ren Fail 2013, 35:648-653.
30. Yokogoshi H., Oda H. Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high-cholesterol diet. Amino Acids 2002, 23:433-439.